

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/841,025	04/24/2001	Judith Aronhime	1662/52602	6176	
26646 7:	590 04/30/2002				
KENYON & KENYON			EXAMINER		
ONE BROAD NEW YORK, I			HUANG, EVELYN MEI		
			ART UNIT	PAPER NUMBER	
			1625	1	
			DATE MAILED: 04/30/2002	8	

Please find below and/or attached an Office communication concerning this application or proceeding.

	_	Application	No.	Applicant(s)				
• Office Action Summary		09/841,025		ARONHIME ET AL.				
		Examiner		Art Unit				
	,	1	na	1625				
The MAILING DATE	of this communication app	Evelyn Hua			ess			
Period for Reply	••			•				
after SIX (6) MONTHS from the ma If the period for reply specified abov If NO period for reply is specified ab	HIS COMMUNICATION.  e under the provisions of 37 CFR 1.13 ling date of this communication.  e is less than thirty (30) days, a reply ove, the maximum statutory period we ended period for reply will, by statute, or than three months after the mailing	36(a). In no eventy within the statutowill apply and will apply and will applicate the	, however, may a reply be tim ry minimum of thirty (30) days expire SIX (6) MONTHS from t ation to become ABANDONED	nely filed s will be considered timely. the mailing date of this comm O (35 U.S.C. § 133).	nunication.			
1) Responsive to comr	munication(s) filed on	·						
2a) This action is FINAL	2b)∏ Thi	is action is n	on-final.					
closed in accordance	n is in condition for allowa e with the practice under				nerits is			
Disposition of Claims								
4)	e pending in the application n(s) is/are withdrav		ideration					
<u></u>		WII IIOIII COIIS	ideration.					
	5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected.							
7) Claim(s) is/are	-							
8) Claim(s) <u>1-123</u> are si	•	election rea	uirement.					
Application Papers	,							
9) The specification is of	jected to by the Examiner	r.						
10)☐ The drawing(s) filed o	n is/are: a)□ accep	oted or b) o	ojected to by the Exam	miner.				
	uest that any objection to the		•	` ,				
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.								
	drawings are required in rep	•	e action.					
12) The oath or declaration	•	aminer.						
Priority under 35 U.S.C. §§ 11								
13) Acknowledgment is r	_	n priority unde	∍r 35 U.S.C. § 119(a)	)-(d) or (f).				
a) ☐ All b) ☐ Some * o	•							
<u></u>	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
application	ertified copies of the prior from the International Bur led Office action for a list of	reau (PCT R	ule 17.2(a)).		ige			
14) Acknowledgment is ma	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation o 15)☐ Acknowledgment is m	f the foreign language pro ade of a claim for domesti							
Attachment(s)		· -						
Notice of References Cited (PTC2)  Notice of Draftsperson's Patent     Information Disclosure Statement	Drawing Review (PTO-948)	5		(PTO-413) Paper No(s). Patent Application (PTO-1				

Application/Control Number: 09/841,025

Art Unit: 1625

## Election/Restrictions

Page 2

1. This application contains claims directed to the following patentably distinct species of the claimed invention:

- I. Claims 10-17, 90, 91, 99, and claims 8, 116-121 in part, drawn to anhydrous Zolpidem hemitartrate Form C, its composition, method of use and process of making.
- II. Claims 18-26, 92-98, 100, and claims 1, 2, 6, 116-121 in part drawn to Zolpidem hemitartrate Form D monohydrate, its composition, method of use and process of making.
- III. Claims 27-36, 101-103, and claims 1, 3-6, 116-121 in part, drawn to Zolpidem hemitartrate Form E, its composition, method of use and process of making.
- IV. Claims 37-44, 104, and claims 6, 9, 116-121 in part, drawn to Zolpidem hemitartrate Form F methanolate, its composition, method of use and its process of making.
- V. Claims 45-51, 105-109, and claims 6, 7, 9, 116-121 in part, drawn to Zolpidem hemitartrate Form G solvate, its composition, method of use and its process of making.
- VI. Claims 52-57, 110-113, and claims 9, 116-121 in part, drawn to Zolpidem hemitartrate Form H, its composition, method of use and its process of making.
- VII. Claims 58-65, 114-115, and claims 1, 3, 6, 116-121 in part drawn to Zolpidem hemitartrate Form L dihydrate, its composition, method of use and process of making.
- VIII. Claims 66-89, drawn to a process for making Zolpidem hemitartrate.
- XI. Claims 122-123, and claims 116, 121 in part, drawn to a micronized Zolpidem hemitartrate Form A.

١.

Application/Control Number: 09/841,025

Art Unit: 1625

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-9, 116-121 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

2. A telephone call was made to Mr. Birde on 4-12-2002 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 09/841,025 Page 4

Art Unit: 1625

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn Huang whose telephone number is 703-305-7247. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman can be reached on 703-308-4698. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

**Primary Examiner** 

Art Unit 1625

April 26, 2002